As a long term share holder I can understand your frustration. The original roll out plan from the bottom up was not working with placements going to some Derms who were not utilizing the machine in the most effective manner. I believe IMHO, that the new emphasis on Medical Institutions and Academicians will be more effective in a top-down approach that also could assist in providing the necessary data that is needed for insurance re-imbursement. High profile meetings with information coming out on the machines' benefits like those announced in the last two days should help in creating demand.
If you decide to pull the plug prior to the EOY for loss right offs, good luck to you.
"Dr. med. Rolf Ostendorf, who has also been working with the MelaFind® system for over one year at Zent Derma in Monchengladbach, Germany, presented MelaFind® data during the workshop. “MelaFind® provides doctors with images and data they can incorporate into the complete skin cancer examination. When used correctly, the detection, diagnosis and management of melanoma may be greatly improved by technologies like MelaFind®. Human intelligence cannot be replaced, but emerging modern diagnostic tools that aid doctors are proving to be the future of dermatology.”
" “The majority of patients are not aware that skin cancer is highly treatable at an early stage, but smart technologies like MelaFind® are helping them understand this better, while also helping dermatologists in monitoring and managing high-risk patients. A great and safe complement to mole mapping and other imaging devices for skin tumors, the important data and images that MelaFind® provides deep below the skin’s surface serve as a modern assist to our traditional methods (ABCDPRUs and dermoscopy). The more information we have, the better the patient outcome.” Dr. med. Marcella Kollmann-Hemmerich
"Prof. Dr. med. Welzel, who recently acquired a MelaFind® unit for research, commented, “Modern non-invasive diagnostic technologies like MelaFind® are quickly becoming the standard-of-care in dermatology as they enrich and complement dermatologists’ skin cancer examinations by providing important images and objective data,"
" are theysame "expert analysts" the capt was throwing in my face who were saying that mela's pps was going to the moon? The capt was quick to point out to all readers that these guys were obviously better at stock analysis than I?"
Why are you so obsessed with me Dancer Man?
Are you really that disappointed that I will not bow down to you like your lackey hacks that you probably pay to stroke your ego?
If you are going to quote me, let's make sure you get the quote right.
""Fish has consistently proven his intellectual superiority over you, fancyboy. Don't be jealous of him, learn from him." Marcel
"Post of the New Year" Me
"Julie E. Russak, M.D., FAAD, a specialist in skin cancer and melanoma, will keynote the session discussing how MelaFind® has aided her biopsy decision making process during melanoma examinations as well as in her ability to communicate with patients about the state of their skin lesions. Dr. Russak will also speak about how she has integrated the quick, painless MelaFind® evaluation into the workflow at Russak Dermatology Clinic, her thriving midtown Manhattan dermatology practice. Dr. Russak is a Board Certified Dermatologist, a Fellow of the American Academy of Dermatology, a member of the American Society of Dermatologic Surgery, and a Volunteer Faculty in Dermatology at Mount Sinai Hospital. In addition to extensive research in Cutaneous Oncology, Dr. Russak has published multiple journal articles and authored a chapter for a prominent skin cancer textbook. She was also the editor of the July 2012 issue of the Dermatologic Clinic’s update on Melanoma and Pigmented Lesions."
" The Clinical Advisory Meeting will gather thought leaders in the field of medical dermatology to discuss the use, clinical value and future potential of MelaFind®, MELA Sciences’ optical imaging technology. Gary Goldenberg, MD, Assistant Professor, Dermatology and Pathology, and Medical Director of the Dermatology Faculty Practice at Mount Sinai’s Department of Dermatology will chair the meeting. Dr. Goldenberg has been using the Company’s MelaFind® optical diagnostic device in clinical practice for over a year.
Dr. Goldenberg, commented, “MELA Sciences is a true pioneer in bringing innovative optical imaging technology to the challenging process of melanoma diagnosis. MelaFind® data and images literally provide dermatologists with ‘another set of eyes’ to help them in their assessment of pigmented skin lesions for possible melanoma. Like other imaging technologies, there seems to be much additional potential for their technology to aid in the diagnosis of skin disorders.” "
"MELA Sciences, Inc. (MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, announces the Company will participate in the 16th Annual Mount Sinai Winter Dermatology Symposium in New York City, December 6-8, 2013. In conjunction with the Symposium, MELA will also host its second Clinical Advisory Meeting on Friday, December 6, 2013."
I seriously doubt that they will be releasing much info prior to the first of the year if you are holding out for that.
Personally, waiting now for 10K around second week of March. From the CC, that's when Mr C indicated more info on company's direction besides the occasional press releases.
Well here is a brilliant idea for you General, although I do believe that I have proposed this one before, why don't you send a letter to JAMA expressing your science and points of view and see if they print it? You can sign it as THE ANONYMOUS YAHOO MB HACK. 8)
A.F. is a real piece of work. He's tried to do a real hatchet job on MELA including a P.O.S. hearsay info blog on his last MELA bashing.
Have you ever read "The Dendreon Effect" by Mitchell? Amazon kindle download for $9.99. His boss is a central figure in that book. Some real enlightenment into how the small biotechs are manipulated.
"cpt: "I'm in the green with CYTX "
You are a LIAR"
No, I'm not but you are lying your aze off about CYTX being in the Dancer Newsletter. You guys knew nothing about the CYTX spike until I brought it up on the board here. Around twenty minutes latter Armyfruitcake showed up on CYTX squawking about FEE.
Pikstox called it right with you guys, you start crowing about something after the fact.
I'm in the green with CYTX General however, that stock is being played just like MELA.
UPS close to 52 week high.
Good call on your part pulling the plug on TSLA, AH not good.
Sure, sure Dancer Man, like I said rriiigggghhhhhttttttttttt.
My guess, your lackey hacks jumped on the band wagon when they saw my post here, nothing prior to that point and as for the General, I'm guessing that he posted that from the hip and there was no reco for CYTX.
Who's nobody, you and your IDIOT lackeys?
I'm holding CYTX, another reco from the same news letter that reco MELA some time ago.
I have no reason to B.S. anyone on this board like the General did with his lame statement of you releasing a news letter on it last night when the stock opens this morning up 40% plus. A little late for the game in stroking your ego Dancer Man.
One would think that for an M.I.T. graduate that he would have thought that one out a little better.
What a BUFFOON!!!
I've been holding CYTX since I've been talking about it on this board, my guess is that you discovered it here. Another good product with questionable management, like MELA, it has been floundering. MELA has the NGIC, CYTX today, MELA soon.
"Was recommended in the Fncydansir Stock-Picking Newsletter last night." General
If you're going to stroke your Boss ego DUMMY, you might at least have the intelligence to bring it up before the news breaks.